

Azetukalner (Kv7 Potassium Channel Opener)	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
X-TOLE2: Epilepsy - Focal Onset Seizures (FOS)			Patient recruitment complete	
X-TOLE3: Epilepsy - Focal Onset Seizures (FOS)				
X-ACKT: Epilepsy - Primary Generalized Tonic-Clonic Seizures (PGTCS)				
X-NOVA2   X-NOVA3: Major Depressive Disorder (MDD)				
X-CEED: Bipolar Depression (BPD)				
Early-Stage Ion Channel Modulators	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
XEN1120: Kv7 Potassium Channel Opener - Pain Indications				
XEN1701: Nav1.7 Inhibitor - Pain Indications				
Kv7 Potassium Channel Openers ( <i>Epilepsy, pain, and neuropsychiatric indications</i> )				
Nav1.7 Sodium Channel Inhibitors ( <i>Pain indications</i> )				
Nav1.1 Sodium Channel Openers ( <i>Dravet Syndrome</i> )				
Partnered Program	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
NBI-921355 - Nav1.2/1.6 Inhibitor (Epilepsy) – Neurocrine Biosciences				

This chart displays pipeline drug candidates currently undergoing clinical and pre-clinical testing in a variety of disease indications. The safety and efficacy of these investigational drug candidates have not been fully evaluated, and they have not yet been approved for use by any regulatory authorities.